Oncobiologics is a Cranbury, NJ-based biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. The company is advancing a pipeline of 11 biosimilar products, two of which are currently in clinical development. It is led by founder and CEO Pankaj Mohan, Ph.D., and operates from a 50,000 sq. ft. fully-integrated R&D and manufacturing facility in Cranbury, NJ. Oncobiologics' core technology is its proprietary BioSymphony™ biosimilar platform. The company intends to use the financing proceeds to continue development and expansion of the BioSymphony platform and to advance its preclinical and clinical programs. The recent financing strengthens its balance sheet to support those development activities. Oncobiologics is a privately held biopharmaceutical company focused on developing biosimilars and next-generation biotherapeutics. The company operates from a 40,000 sq. ft. fully integrated R&D and manufacturing facility in Cranbury, New Jersey. It was formed by a team of industry experts from firms including Eli Lilly, Bristol-Myers Squibb, Amgen, Genentech, Merck and Pfizer. Oncobiologics is advancing a pipeline of biosimilars and novel biologic therapies and aims to continue executing its business and technical plans. The company has secured strategic backing to support its development and commercialization efforts. Financial details beyond the strategic investment announcement were not disclosed.

Total raised

$31M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2015